Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 combined with Letrozole in HR+/HER2- Advanced Breast Cancer
NCT05744687Phase 3Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing SPH4336 + Letrozole with Placebo + Letrozole (2 arms). Primary endpoints: Objective Response Rate at 3 years and Progression-Free Survival at 3 years. Started Apr 2023; status: recruiting.
02
Drugs
SPH4336
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05744687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744687.